The Limited Times

Now you can see non-English news...

They will vaccinate 924,000 boys between 12 and 17 years old with Moderna and announce that 'August will be the month of the second doses'


They defined the enrollment of adolescents with risk factors. At the same time, they want to reach 60% of those over 50 immunized with the full scheme next month.

Emilia vexler

07/27/2021 3:18 PM

  • Clarí

  • Society

Updated 07/27/2021 3:36 PM

When the vaccines were unloaded from the two Aerolineas Argentinas planes in Ezeiza and received by the Chief of Staff, Santiago Cafiero, it was already a fact that Argentina would begin to apply


doses to

adolescents with comorbidities.

The issue was how.

And since when.

This Tuesday, without major differences between each political line, the Federal Health Council (COFESA) reached an agreement on the vaccination strategy for the 12 to 17-year-old group with risk factors.

It was agreed that it should be "urgent".

And it has already been defined which groups will be a priority.

"We agree that August

will be the month of the second doses to have an impact on the decrease in mortality


hospitalizations given

the potential risk of presenting persistent circulation of the

delta variant

," said the Minister of Health of the Nation, Carla Vizzotti, in the meeting that took place in the Palacio San Martín.

Which groups will be prioritized in the 12 to 17 age range

• Type 1 or 2 diabetes.

• Obesity grade 2 (BMI> 35) and grade 3 (BMI> 40).

• Chronic cardiovascular disease: heart failure, coronary disease, valvular heart disease, cardiomyopathy, pulmonary hypertension.

Congenital heart disease.

• Chronic kidney disease (including chronic dialysis and transplant patients).

Nephrotic syndrome.

• Chronic respiratory disease: chronic obstructive pulmonary disease (COPD), cystic fibrosis, interstitial lung disease, severe asthma.

Oxygen therapy requirement.

Severe airway disease.

Asthma hospitalizations.

• Liver disease: Cirrhosis.

Autoimmune hepatitis.

• People living with HIV regardless of CD4 and CV.

• Patients on the waiting list for solid organ transplantation and hematopoietic cell transplantation.

• Oncology and oncohematology patients with recent or “active” diagnosis.

• People with active tuberculosis.

• People with intellectual and developmental disabilities.

• Down's Syndrome.

• People with autoimmune diseases and / or immunosuppressive, immunomodulatory or biological treatments.

• Adolescents who live in places of long stay.

• Pregnant people from 12 to 17 years old with individual indication.

• People with a valid unique disability card (CUD).

• People with ANSES disability pension even if they do not have CUD.

• People with ANSES pension for transplants even if they do not have CUD.

The Undersecretary of Health Strategies, Juan Manuel Castelli pointed out that it is estimated that 22 percent of the aforementioned age group would meet these criteria, which would mean 924,000 adolescents and 1,848,000 doses of Moderna's vaccine.

The interval of application of the two doses of Moderna is 28 days.

The Ministry of Health of the Nation will meet this Wednesday with the

Argentine Society of Pediatrics (SAP)

to specify which adolescents, that is, with which diseases, will be vaccinated first.

In addition, a new COFESA finding next week will establish that each district accelerate the application of second doses

to complete the schemes started


During the

meeting at the San Martín Palace

with the 24 ministers of Health of the country, the Minister of Health of the Nation, Carla Vizzotti, specified that "as of this Thursday, the jurisdictions will

begin to register the prioritized adolescent population

and the preparation of the first batch of the Moderna doses ".

It is estimated that there are about

900,000 adolescents

of those ages with metabolic diseases, obesity, diabetes, respiratory, cardiovascular and neurological conditions, among other conditions, who will receive this brand of vaccine.

The modern vaccine will begin to be applied among children under 18 years of age with comorbidities.

The European Medicines Agency (EMA) approved the use of this coronavirus vaccine for young people between 12 and 17 years old.

Said thumbs up - or that of the FDA, which is like our Anmat in the United States - was expected by the Government to advance its application in adolescents.

Argentina recently received a

donation of Moderna vaccines

from the US government.

There are 3.5 million doses that are stored in the Andreani logistics center.

It is the second vaccine after Pfizer's licensed for adolescents in the 27 countries of the European Union (EU).

What to know about Moderna

Moderna's vaccine is considered "top of the line" among coronavirus vaccines.

With messenger RNA technology, it requires

two doses and demonstrated 94.1% efficacy against symptomatic Covid-19.

It presented good results in the adolescent population and generated neutralizing titers (antibodies) against the new variants of the virus in immunized people, according to various clinical trials.

According to the World Health Organization (WHO), it can be stored at a temperature between 2 ° C and 8 ° C for 30 days.

This makes it

easier than Pfizer in terms of logistics and distribution.

On May 25, Moderna announced that its coronavirus vaccine is

"highly effective" in adolescents between the ages of 12 and 17

, according to the full results of the TeenCOVE clinical trial.

More than 3,700 adolescents between the ages of 12 and 17 in the United States participated in that research, of whom two-thirds received the vaccine and one-third placebo.

"After two doses, no cases of Covid-19 were observed in the vaccinated group ... against four cases in the placebo group, resulting in

a vaccine effectiveness of 100% 14 days after the second dose."

Moderna said in its statement.

The laboratory that created it also began a study in 6,750 children 6 months to 11 years (KidCOVE) whose results have not yet presented.

The other messenger RNA vaccine for boys

Earlier this Tuesday and after a year since negotiations began, Vizzotti announced that Argentina

signed a "binding agreement" with the Pfizer laboratory

for the provision of 20 million doses of vaccines against the coronavirus.

Those doses will arrive in the country this year, once the final agreement related to logistics issues that will define delivery and reception times is signed.

It is worth remembering that Pfizer vaccines would also target adolescents between 12 and 17 years of age.

At the request of the FDA,

Pfizer and Moderna are expanding the study of their vaccines in boys and girls ages 5 to 11.

Pfizer vaccines require special transporters, "ultra cold" boxes, which keep them at 70 degrees below zero, from which the delivery time will be derived, estimated between the signing of the definitive agreement - not yet defined - and December.

Vizzotti assured that they will serve to "accelerate the vaccination of 2021 and think about

the strategy of 2022".

In this context, he also announced that on Monday the payment of the first

200,000 doses of the Chinese Cansino vaccine

was signed

as part of the 5.4 million contract for 2021. Those doses will be received in the coming days and it is not ruled out that they serve to complete the schemes, before the critical lack of the second doses of Sputnik V.

The vaccine, one of the three developed in China that is currently applied in Latin America, was produced by the pharmaceutical company CanSino Biologics together with the Beijing Institute of Biotechnology, requires a single dose and can be stored at a temperature between 2 and 8 degrees;

that is, it does not require freezing, which facilitates its logistics.

Vizzotti clarified that



are not restarted

, the effect of the first dose is not lost", and indicated that until today Argentina received 41,833,840 doses, of which 90% (37,165,114) have been distributed to each of the jurisdictions provided by the national government.

He explained that the stock "at the central level or in the distribution process" amounts to 5,616,166 remaining doses, of which "3.5 million are Moderna vaccines, the largest donation made by the United States to a Latin American country. ", and that were reserved for adolescents with comorbidities;

551,400 from Astrazeneca, and 1.2 million from Sinopharm.

To date "30,230,385 doses have been applied";

"24,096,445 people already have the first dose and 6,133,940 the two doses, that is, they completed the scheme," he said.

On the other hand, the minister stressed that the Ethics Committee of the Ministry of Health of the Nation approved the interchangeability clinical trial, to which the Moderna vaccine was added, to investigate with all the vaccines available in Argentina. 


Look also

After more than a year of controversy, the Government announced the agreement to buy 20 million vaccines from Pfizer

When and why did the Government decide to back down in its fight with Pfizer and negotiated a millionaire purchase

Source: clarin

All life articles on 2021-07-27

You may like

Trends 24h

Life/Entertain 2021-09-15T22:50:31.051Z
Life/Entertain 2021-09-16T05:08:37.723Z


© Communities 2019 - Privacy